Patents by Inventor Jane Kendrew

Jane Kendrew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS COMPRISING FIXED INTERMITTENT DOSING OF CEDIRANIB
    Publication number: 20210322415
    Abstract: Methods comprising repeating cycles of administration of a composition comprising cediranib according to a fixed intermittent dosing regimen comprising administration of an effective amount of the composition comprising cediranib on one or more consecutive days of a cycle followed by one or more consecutive days of rest on which said composition is not administered are disclosed herein, and may be used as monotherapy or may comprise administration of one or more partner drugs or therapies and may be used in combination therapy.
    Type: Application
    Filed: February 14, 2017
    Publication date: October 21, 2021
    Applicants: ASTRAZENECA AB, THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Simon BARRY, Jane KENDREW, Tony HO, Stephen Robert WEDGE, Susan Percy IVY, Elise KOHN, Jung-Min LEE
  • TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
    Publication number: 20120114667
    Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 10, 2012
    Applicant: MEDIMMUNE LIMITED
    Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry
  • TARGETED BINDING AGENTS DIRECTED TO a5ß1 AND USES THEREOF
    Publication number: 20120107324
    Abstract: The invention relates to targeted binding agents against ?5?1 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to ?5?1. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of ?5?1 and as diagnostics.
    Type: Application
    Filed: December 21, 2009
    Publication date: May 3, 2012
    Inventors: Catherine Anne Eberlein, Ian Foltz, Jaspal Singh Kang, Jane Kendrew, Avril Alfred, Simon Thomas Barry